<DOC>
	<DOC>NCT00420485</DOC>
	<brief_summary>This study will evaluate the Maximum Tolerated Dose and dose limiting toxicity of gimatecan administered orally in patients with advanced solid tumors</brief_summary>
	<brief_title>Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criteria: Advanced or metastatic cancer 18 years and above Exclusion criteria: Previous treatment with 4 or more cycles of carboplatin; Previous treatment with 2 or more courses of nitrosourea or mitomycin; Previous radiation therapy greater than or equal to 25% of the hematopoietic reserve; Severe and/or uncontrolled medical conditions Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Dose Limiting Toxicity</keyword>
	<keyword>Topoisomerase-1 Inhibitor</keyword>
</DOC>